Please assess the completion status of the following clinical trial:

Trial Title: PD1-CD19-CART in Patients With r/r B-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Have the capacity to give informed consent;~2. ALL patients with the age between 18 and 70 years old;~3. Expected survival \>3 moths;~4. With no severe heart and lung disease;~5. Previously confirmed diagnosis as CD19+ NHL within 6 months;~6. Hematological index as following, white blood cell (WBC)≥1.5×10\^9/L，absolute neutrophil count (ANC) ≥0.8×10\^9/L, Platelet count≥50×109/L, Hemoglobin (Hgb) ≥ 90mg/L, lymphocyte count≥ 0.4×10\^9/L；~7. Blood biochemical index as no more than 1.5\* ULN, including total bilirubin (TBIL), transglutaminase (AST), alanine aminotransferase (AST), Creatinine (SCr), Urea in patients with no tumor metastasis in liver and kidney; Blood biochemical index no more than 5\* ULN in patients with tumor metastasis in liver and kidney;~8. With a stable cardiac function, the left ventricular ejection fraction (LVEF) ≥ 55%;~9. Virological tests were negative for EBV, CMV, HIV, TP and HCV; a negative HBV DNA test is acceptable if HBsAg is positive;~10. ECOG \<2;~11. Relapsed or refractory (r/r) NHL including, Diffuse large B cell lymphoma(DLBCL, NOS), stage Ⅲ-Ⅳ;Primary mediastinal large B-cell lymphoma (PMBL), stage Ⅲ-Ⅳ; High grade B-cell lymphoma (HGBL), stage Ⅲ-Ⅳ; Mantle cell lymphoma (MCL), stage Ⅲ-Ⅳ; follicular lymphoma (FL), stage Ⅲ-Ⅳ and with aggression. r/r NHL defined as following, demonstrate disease that persists or relapse after achieving complete response (CR) after \> 2 cycles of standard chemotherapy, or relapse after autologous hematopoietic stem cell transplantation (auto-HSCT), or not achieving CR after auto-HSCT.~Exclusion Criteria:~1. Pregnant or lactating women;~2. With a pregnancy plan in the next 2 years;~3. Prior treatment of anti-GVHD therapy;~4. Acceptance of allogeneic stem cell transplant (ASCT);~5. Isolated extramedullary relapse of ALL;~6. Severe mental disorders, active autoimmune diseases, active infectious diseases, severe cardiovascular diseases;~7. Partial prothrombin time or activated partial thromboplastin time or international standardized ratio \> 1.5\*ULN without anticoagulant treatment;~8. History of other type of maligant tumors;~9. Any circumstances that possibly increase the risk of subjects or interfere with study results, which judged by investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PD1-CD19-CART (Type: EXPERIMENTAL): Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CART infusion. A dose of PD1-CD19-CART will be infused on day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).